Borrelia B-cell Diagnostics

Launched by UNIVERSITY CHILDREN'S HOSPITAL, ZURICH · Sep 13, 2023

Keywords

ClinConnect Summary

The Borrelia B-cell Diagnostics (BRILLIANT) study is a clinical trial aimed at improving how we diagnose Lyme disease in children. Researchers want to develop a new test to detect the immune response specifically to Borrelia burgdorferi, the bacteria that causes Lyme disease. This study is important because current tests can sometimes miss early infections or give false positive results in patients who have recovered. By better understanding the immune system's reaction to this infection, the study hopes to create more accurate diagnostic tools and gather valuable information on the disease's effects.

Children aged 0 to 17 years who are being evaluated for Lyme disease at the University Children's Hospital Zurich may be eligible to participate. The study will include those who show symptoms suggestive of Lyme disease, and it will also look at healthy children as a comparison group. Participants can expect to provide blood samples and clinical information, which will help researchers learn more about Lyme disease and its diagnosis. Importantly, children with certain immune system disorders will not be included in the study. Through this research, we hope to improve the understanding and treatment of Lyme disease in children.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients presenting at the ED with differential diagnosis of LD according to the treating physician
• Exclusion Criteria:
• • Patients will be excluded in cases of primary or secondary immunodeficiency